Plasma-Based Genotyping Aids Targeted Tx of Metastatic NSCLC
THURSDAY, Oct. 18, 2018 -- Integration of plasma next-generation sequencing (NGS) into the routine management of metastatic non-small cell lung cancer (NSCLC) results in an increase in the detection of therapeutically targetable mutations, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 18, 2018 Category: Pharmaceuticals Source Type: news

A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue
Due to the high rate ofEGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Emily Wynja, MSIV, Jenna Hove, BSN, Steven F. Powell, MD Source Type: news

New Breakthrough Therapy Designated for Thyroid Cancer and NSCLC
LOXO-292, which selectively targetsRET and has demonstrated preclinical activity against activatingRET fusions/mutations, holds promise. (Source: CancerNetwork)
Source: CancerNetwork - October 16, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

In NSCLC, Longer Survival With Brigatinib Than Crizotinib
Longer progression - free survival in those with ALK - positive dz who did not previously take ALK inhibitor (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 16, 2018 Category: Respiratory Medicine Tags: Oncology, Pulmonology, Journal, Source Type: news

In NSCLC, Longer Survival With Brigatinib Than Crizotinib
MONDAY, Oct. 15, 2018 -- Among patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor, progression-free survival is significantly longer in those who receive... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 15, 2018 Category: Pharmaceuticals Source Type: news

ALK Testing Rates Increasing in NSCLC Patients ALK Testing Rates Increasing in NSCLC Patients
Testing for mutations in the ALK gene in patients with non-small-cell lung cancer (NSCLC) who are candidates for targeted therapy nearly doubled from 2011 to 2016, according to a new study in U.S. community practices.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 12, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Can Surgery Type Predict Opioid Abuse in NSCLC?
A study shows NSCLC patients who undergo minimally invasive procedures are less likely to use opioids long-term. (Source: CancerNetwork)
Source: CancerNetwork - October 10, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

More Surveillance Not Tied to More Survival in NSCLC (CME/CE)
(MedPage Today) -- No benefit to more than biannual CT-based follow-up, researchers say (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 10, 2018 Category: Hematology Source Type: news

Increased survival in patients with metastatic NSCLC receiving treatment in academic centers
(International Association for the Study of Lung Cancer) Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs). An overall histology-dependent survival was also noted in patients with adenocarcinoma verses squamous cell carcinoma and varied by treatment facility. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2018 Category: Cancer & Oncology Source Type: news

Novel technology enables detection of early-stage lung cancer when surgical cure still is possible
(Elsevier) To improve outcomes for patients with non-small-cell lung carcinoma researchers are developing a blood test to detect lung cancer earlier in the disease. A report in The Journal of Molecular Diagnostics describes a new technology, electric field-induced release and measurement (EFIRM) that is both highly sensitive and specific in detecting two epidermal growth factor receptor (EGFR) mutations associated with lung cancer in the blood of NSCLC patients with early-stage disease. This platform is relatively inexpensive and capable of high-throughput testing. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 8, 2018 Category: International Medicine & Public Health Source Type: news

Three Digital Core Biopsies Sufficient to Determine PD-L1 Expression in NSCLC
Four or more biopsies proffer little additional benefit, found a study presented at the IASLC 19th World Conference on Lung Cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Pembrolizumab Alone or With Chemotherapy for PD-L1 –Positive NSCLC?
Pembrolizumab plus chemotherapy failed to improve survival compared with pembrolizumab alone in patients with non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Dacomitinib (Vizimpro) Approved for EGFRm NSCLC Dacomitinib (Vizimpro) Approved for EGFRm NSCLC
Another targeted agent is now available for use in the first-line treatment of metastatic non-small cell lung cancer (NSCLC) that harbors EGFR mutations.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Vizimpro (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
September 27, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Vizimpro [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2018 Category: Drugs & Pharmacology Source Type: news

Tecentriq Misses OS Mark in Nonsquamous NSCLC
(MedPage Today) -- But study met co-primary endpoint of PFS improvement (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - September 27, 2018 Category: Respiratory Medicine Source Type: news

Breakthrough Treatment Helps Prolong Life for People with Metastatic Lung Cancer
September 26, 2018—(BRONX, NY)—When lung cancer has spread, or metastasized, to other parts of the body, standard chemotherapy offers only a modest survival benefit. Now, in a major advance described in today’s issue of theNew England Journal of Medicine, an international team, including researchers from Albert Einstein College of Medicine and Montefiore Health System, report that combining chemotherapy with the immunotherapy drug Keytruda extends the lives of people with metastatic squamous non-small cell lung cancer (NSCLC) by more than 40 percent compared with chemotherapy alone—a significant imp...
Source: Einstein News - September 26, 2018 Category: Universities & Medical Training Source Type: news

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - September 26, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

NSCLC_treatment_sequencing_survey
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC  More than one-third of physicians report not having sufficient information to decide on how to sequence specific targeted lung cancer treatmentsSurvey findings presented today as a late-breaking abstract at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 26, 2018 Category: Research Source Type: news

No Survival Benefit with Cranial RT for NSCLC
(MedPage Today) -- Better disease-free survival, fewer brain mets (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - September 25, 2018 Category: Radiology Source Type: news

Consolidation Boosts Outcomes in Stage III NSCLC
(MedPage Today) -- Median time to metastasis, death more than doubled with post-CRT pembrolizumab (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - September 24, 2018 Category: Radiology Source Type: news

Roche ’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Roche today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA trials, which showed that entrectinib shrank tumours (objective response rate; ORR) in 77.4% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Roche today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA trials, which showed that entrectinib shrank tumours (objective response rate; ORR) in 77.4% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

OS Comparable with Radiation, Ablation Therapy in Stage 1 NSCLC
(MedPage Today) -- But more unplanned hospital readmissions with invasive procedures (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - September 23, 2018 Category: Radiology Source Type: news

Hyperprogression in NSCLC Patients With PD-1/PD-L1 Inhibitors
A study shows hyperprogressive disease (HPD) occurred more commonly among patients with pretreated non-small cell lung cancer (NSCLC) receiving PD-1/PD-L1 inhibitors. (Source: CancerNetwork)
Source: CancerNetwork - September 21, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Europe OKs Brigatinib for ALK+NSCLC, Other Products Europe OKs Brigatinib for ALK+NSCLC, Other Products
A positive opinion was granted for brigatinib, as well as mogamulizumab, a generic version of paclitaxel, and three new biosimilar pegfilgrastim products.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Survival Similar After Thermal Ablation, Stereotactic Radiation Therapy for NSCLC Survival Similar After Thermal Ablation, Stereotactic Radiation Therapy for NSCLC
Survival of patients with stage 1 non-small cell lung cancer (NSCLC) is similar after thermal ablation and stereotactic radiation therapy, respectively, according to data from the U.S. National Cancer Database.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Is thermal ablation effective for treating NSCLC?
Thermal ablation is safe and effective for treating early-stage non-small cell...Read more on AuntMinnie.comRelated Reading: CT finds heart disease in patients with lung cancer CADx volumetry predicts lung cancer recurrence on CT ASTRO updates guideline for lung cancer radiation therapy Novel PET tracer may improve NSCLC patient management FDG-PET/CT could improve treatment for NSCLC patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2018 Category: Radiology Source Type: news

PET/CT makes case for directing cervical cancer treatment
Can FDG-PET/CT be used to direct the treatment of locally advanced cervical...Read more on AuntMinnie.comRelated Reading: Extremity PET/CT scans unnecessary for melanoma patients FDG-PET/CT could improve treatment for NSCLC patients ASTRO: PET predicts outcomes in vulvar cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 14, 2018 Category: Radiology Source Type: news

Next-Gen ALK Inhibitor Shows Promise in Advanced NSCLC
(MedPage Today) -- Brigatinib demonstrated significant CNS penetration, regardless of prior treatment (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 12, 2018 Category: Hematology Source Type: news

Corticosteroids at Time of PD-L1 Blockade May Reduce Efficacy in NSCLC
Taking corticosteroids at the time of treatment initiation with PD-L1 inhibitors may lead to inferior outcomes in patients with non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 10, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC
On September 05 2018, Roche was notified by the U.S. Food and Drug Administration (FDA) that the review period for the supplemental Biologics License Application (sBLA) for TECENTRIQ ® (atezolizumab) in combination with Avastin® (bevacizumab), carboplatin and paclitaxel for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) has been extended by three months. (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2018 Category: Pharmaceuticals Source Type: news

Drug Conjugate Advances for Poor-Prognosis NSCLC
(MedPage Today) -- Good results in small study of trastuzumab linked to antimicrotubule agent (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 4, 2018 Category: Hematology Source Type: news

Drug Conjuagate Advances for Poor-Prognosis NSCLC
(MedPage Today) -- Good results in small study of trastuzumab linked to antimicrotubule agent (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - September 2, 2018 Category: Respiratory Medicine Source Type: news

Biodesix Makes the Case for VeriStrat Through New Study
The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC). VeriStrat is a multivariate, mass-spectrometry based test that measures circulating proteins in the blood serum or plasma of patients with NSCLC. Test results assign a good (VS Good) or poor (VS Poor) classification to patient samples. Multiple studies support that patients with a VS Good result have a better prognosis than patients with a VS Poor result, independent of curr...
Source: MDDI - August 31, 2018 Category: Medical Devices Tags: IVD Business Source Type: news

Mutations, drugs drive cancer by blurring growth signals
(University of California - San Francisco) Genetic mutations in a form of non-small cell lung cancer (NSCLC) may drive tumor formation by blurring cells' perception of key growth signals, according to a new laboratory study published Aug. 31, 2018, in Science. The research, led by UC San Francisco researchers, could have important implications for understanding and ultimately targeting the defective mechanisms underlying many human cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2018 Category: International Medicine & Public Health Source Type: news

Steroid Use May Blunt Anti-PD-1 Effect in NSCLC
(MedPage Today) -- Lower response rate, PFS, survival with ?10 mg/day baseline dose (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - August 30, 2018 Category: Endocrinology Source Type: news

Inferior Immunotherapy Response When NSCLC Pts on Steroids Inferior Immunotherapy Response When NSCLC Pts on Steroids
In advanced non-small cell lung cancer (NSCLC), patients who use steroids when starting single-agent immunotherapy have inferior clinical responses with immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

NSCLC Survival Longer with Salvage after SABR
(MedPage Today) -- No difference from patients without local recurrence at 5 years (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 28, 2018 Category: Hematology Source Type: news

Utility of Rapid EGFR Genotyping in Advanced Lung Cancer Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
With expedited EGFR genotyping, patients with NSCLC may be able to access effective targeted therapies sooner.JCO Precision Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - August 22, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Anlotinib Promising in Advanced Lung Cancer Anlotinib Promising in Advanced Lung Cancer
The novel tyrosine kinase inhibitor anlotinib improves survival in patients with advanced non-small cell lung cancer (NSCLC), according to Chinese researchers.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Expanded Label for Merck ’s Keytruda (pembrolizumab) in Patients with Metastatic Nonsquamous NSCLC with No EGFR or ALK Genomic Tumor Aberrations
KENILWORTH, N.J.--(BUSINESS WIRE) August 20, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck ’s... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 21, 2018 Category: Drugs & Pharmacology Source Type: news

China National Drug Administration grants rapid approval of Roche ’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - August 20, 2018 Category: Pharmaceuticals Source Type: news

China National Drug Administration grants rapid approval of Roche ’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - August 20, 2018 Category: Pharmaceuticals Source Type: news

Broad Genetic Testing for NSCLC May Not Improve Survival
Compared with routine genetic testing, no improvement seen in unadjusted mortality rate (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 15, 2018 Category: Cancer & Oncology Tags: Oncology, Pathology, Pulmonology, Journal, Source Type: news

Broad Genetic Testing for NSCLC May Not Improve Survival
WEDNESDAY, Aug. 15, 2018 -- Broad-based genomic sequencing does not improve survival compared to routine genetic testing among patients with advanced non-small-cell lung cancer (NSCLC), according to a study published in the Aug. 7 issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 15, 2018 Category: Pharmaceuticals Source Type: news

Genetic Tests Miss ROS1 Status in Some Advanced NSCLC Cases Genetic Tests Miss ROS1 Status in Some Advanced NSCLC Cases
Orthogonal assays are recommended for fusion testing to make sure patients get optimal targeted therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Broad-Based Genomics No Help in NSCLC
(MedPage Today) -- Targeted therapy, survival similar to routine testing (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 7, 2018 Category: Primary Care Source Type: news